FCP
VRTX icon

Fidelis Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Fidelis Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$962K Hold
2,155
– – 0.07% 216
2025
Q4 		$977K Buy
2,155
+136
+7% +$58.6K 0.07% 204
2025
Q3 		$791K Sell
2,019
-3,336
-62% -$1.39M 0.06% 236
2025
Q2 		$2.07M Sell
5,355
-249
-4% -$115K 0.19% 96
2025
Q1 		$2.77M Buy
5,604
+84
+2% +$39.1K 0.29% 72
2024
Q4 		$2.6M Buy
5,520
+55
+1% +$25.5K 0.26% 73
2024
Q3 		$2.57M Buy
5,465
+285
+6% +$137K 0.31% 63
2024
Q2 		$2.41M Buy
5,180
+2,257
+77% +$980K 0.34% 55
2024
Q1 		$1.22M Buy
2,923
+1,138
+64% +$481K 0.19% 99
2023
Q4 		$726K Buy
1,785
+199
+13% +$73.5K 0.16% 129
2023
Q3 		$552K Buy
1,586
+190
+14% +$66.4K 0.19% 121
2023
Q2 		$491K Buy
1,396
+106
+8% +$35.7K 0.18% 133
2023
Q1 		$449K Buy
+1,290
New +$387K 0.19% 127

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelis Capital Partners's VRTX Position: Q1 2026 in Review

Fidelis Capital Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 2,155 shares worth $962K. The position accounts for 0.07% of the portfolio, ranked #216.

Fidelis Capital Partners first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.77M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fidelis Capital Partners held 2,155 shares of Vertex Pharmaceuticals worth $962K as of Q1 2026.
  • Fidelis Capital Partners left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.07% of Fidelis Capital Partners's portfolio in Q1 2026, its #216 holding.
  • Fidelis Capital Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Fidelis Capital Partners's Vertex Pharmaceuticals position peaked at $2.77M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.